3 Top Medtech Stocks Beating Q2 Estimates
Three medical device companies with Composite Ratings in the top 10% of all stocks were building on recent gains with strong quarters Thursday morning.
Cardiac device giant Boston Scientific (BSX) hit a 10-year high in early trading Thursday after its Q2 sales growth and guidance beat expectations, making up for weaker-than-expected margins.
Boston Scientific's sales grew 15% over the year-earlier quarter to $2.12 billion, its strongest growth in nearly a decade and more than $50 million above analysts' consensus.
Cardiac device giant Boston Scientific (BSX) hit a 10-year high in early trading Thursday after its Q2 sales growth and guidance beat expectations, making up for weaker-than-expected margins.
Boston Scientific's sales grew 15% over the year-earlier quarter to $2.12 billion, its strongest growth in nearly a decade and more than $50 million above analysts' consensus.